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Glucuronic	acid	as	a	helix-inducing	linker	in	short	peptides	
Chongyang	Wu,a	Huy	N.	Hoang,a	Ligong	Liua	and	David	P.	Fairliea,b	
A	new	strategy	is	demonstrated	for	making	peptides	helical,	using	
a	 carbohydrate	 to	 bridge	 between	 sidechains	 at	 each	 end	 of	 a	
pentapeptide.	CD	and	NMR	spectra	establish	that	both	an	α-helix	
and	a	310-helix	structure	can	form	depending	upon	the	bridge.		
The	α-helix	is	a	dominant	secondary	structure	in	proteins	with	
important	roles	in	mediating	protein	interactions.1	Helices	are	
often	 found	 at	 protein-protein	 interfaces	 and	 in	 membrane-
spanning	domains	of	proteins.2	 The	 surfaces	 in	most	protein-
protein	 interactions	are	shallow	and	span	 large	areas,	making	
them	difficult	to	reproduce	or	 inhibit	using	small	hydrophobic	
drug-like	 molecules.3	 However,	 short	 synthetic	 peptides	
corresponding	 to	 bioactive	 protein	 α-helices	 can	 span	 large	
surfaces	 and	 have	 high	 binding	 affinities	 due	 to	 multiple	
contacts.	 In	 water	 short	 peptides	 are	 not	 structurally	 well	
defined	due	to	competition	from	solvating	water	molecules	for	
peptide	 NH	 and	 CO	 groups	 that	 otherwise	 form	 helix-
stabilising	 intramolecular	 hydrogen	 bonds.1a Methods	 to	
stabilise	 helical	 structures	 in	 short	 peptides	 have	 been	
developed,	most	notably	using	cyclization	constraints,4	leading	
to	some	successes	in	inhibiting	protein-protein	interactions.5 
Strategies	 that	 have	 been	 developed	 to	make	macrocyclic	
peptides	 helical,	 include	 cross-linking	 amino	 acids	 through	
their	side	chains4	or	head/tail	to	side	chain,6	or	incorporating	a	
hydrogen-bond	surrogate.7	Cross-linking	usually	 connects	 two	
amino	acids	on	the	same	helix	face	(i,	i	+	4,	i	+	7,	i	+	11)	via	an	
appropriate	 linker,	 or	 substitutes	 unnatural	 amino	 acids	with	
functional	groups	that	are	coupling	together.	Such	approaches	
have	 limitations,	 increasing	 synthetic	 complexity,	 reducing	
solubility,	and	inducing	cell	lysis	due	to	membrane	damage.	In	
this	 study	we	 investigate	 the	potential	 to	use	 glucuronic	 acid	
as	 a	 linking	motif	 (Fig.	 1),	 which	 can	 provide	 different	 linker	
sites	 and	 also	 alter	 peptide	 solubility.	 Glycosylation	 is	 a	
common	 post-translational	 modification	 of	 proteins,8	 and	 is	
known	 to	 influence	 protein	 and	 peptide	 folding,9	
recognition,10,11	 targeting11	 and	 stability.10b,12	 While	 carbo-
hydrates	 have	 been	 incorporated	 into	 bioactive	 peptides	 to	
change	structure	and	function,	there	are	few	reports	of	effects	
of	peptide	glycosylation	on	helicity,13	and	it	has	not	been	used	
to	crosslink	amino	acids	in	short	peptides.	
	
Fig.	1	Model	of	D-glucuronic	acid	(yellow)	linking	two	sidechains	at	the	ends	of	a	helical	
pentapeptide	 (green).	 Models	 of	 energy-minimised	 structures	 reveal	 an	 amide	 N	 to	
anomeric	O	distance	(d2)	=	4.4	Å	to	5.9	Å.	This	can	potentially	influence	the	Cα(i)-Cα(i	+	
4)	distance	(d1)	that	defines	an	idealised	α-helix	(d1	=	6.1	Å)	vs	310-helix	(d1	=	7.8	Å),	as	
can	the	length	of	linkers	between	the	sugar	and	the	peptide	backbone.		
We	used	computer	models	 to	compare	 idealised	α-	versus	
310-helices	 stapled	 by	 a	 glucuronic	 acid	 linker	 (Fig.	 1).	 An	α-
helix	is	defined	by	a	Cα(i)	to	Cα(i	+	4)	distance	(d1	=	6.1	Å),	phi	
(–58°)	 and	 psi	 (–48°)	 dihedral	 angles,	 and	 3	 hydrogen	 bonds	
(C(i)	 to	NH(i	+	 4).	 A	 310-helix	 is	 defined	by	 the	 corresponding	
distance	(d1	=	7.8	Å),	phi	(–60°)	and	psi	(–30°)	dihedral	angles,	
and	 4	 hydrogen	 bonds	 (C(i)	 to	 NH	 (i	 +	 3)).	 The	 distance	 (d2)	
between	 lysine	 Nε	 and	 anomeric	 O	 of	 β-D-glucuronic	 acid	
(GlcA)	 ranges	 from	4.4-5.9	Å,	depending	upon	rotation	of	 the	
carbonyl	carbon	(Fig.	1),	encouraging	us	to	explore	it	as	a	helix-
inducing	linker	between	i	and	i	+	4	positions	in	a	peptide.	
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Here	we	 report	 a	 new,	 selectively	 protected,	 glucuronate-
linked	amino	acid	building	block,	Fmoc-Ser(β-D-GlcA(OAll))-OH	
peracetate	5,	suitable	for	solid	phase	peptide	synthesis	(SPPS)	
(Scheme	1).	Peracetylation	of	commercially	available	D-glucu-
ronic	 acid	 1,	 followed	 by	 selective	 hydrolysis	 of	 anhydride	 2	
gave	 acid	3.	 The	 allyl	 ester	 formed	 in	 the	presence	of	DIPEA.	
The	acetate	glycosyl	donor	4	was	coupled	with	Fmoc-Ser-OH	in	
the	presence	of	BF3·O(C2H5)2	 and	molecular	 sieves	 to	 form	5.	
Although	examples	are	known	where	the	anomeric	position	or	
6-carboxylate	 of	 glucuronic	 acid	 is	 linked	 to	 a	 peptide	 back-
bone,13a,14	coupling	via	peptide	side-chains	was	less	studied.15	
	
Scheme	1.	Synthesis	of	a	glycosylate	amino	acid,	Ser(β-D-GlcA)	5,	abbreviated	S*.	
With	5	in	hand,	SPPS	using	Rink-Amide	resin	produced	four	
pentapeptides,	 Ac-S*AAAK-NH2	 (6),	 its	 cyclised	 derivative	 Ac-
(cyclo-1,5)-[S*AAAK]-NH2	(7),	and	sequence	reversed	pairs	Ac-
[KAAAS*]-NH2	 (8)	 and	Ac-(cyclo-1,5)-[KAAAS*]-NH2	 (9),	where	
S*	 represents	 Ser(β-D-GlcA)	 and	 cyclisation	 occurs	 between	
lysine	 ε–amine	 and	 carboxylic	 acid	 of	 GlcA.	 During	 peptide	
assembly,	the	base	promoted	β-elimination16	of	H-5	and	4-OAc	
of	GlcA	to	generate	an	α,β-unsaturated	carboxylate	where	S*	
was	at	the	C-terminus	(e.g.	10	isolated	from	9,	Fig.	S7).		
Structures	 were	 examined	 by	 circular	 dichroism	 spectros-
copy	for	6-10	in	10	mM	phosphate	buffer	pH	7.4.	Uncyclised	6	
was	only	13%	helical	based	on	molar	ellipticity	at	λ	=	220	nm	
(Fig.	 2A),	 but	 increased	 to	 27%	 in	 50%	 TFE	 (Fig.	 S1A).	 The	
corresponding	 cyclized	 peptide	 7	 showed	 34%	 helicity	 (Fig.	
2A).	 Uncyclised	 peptide	 8	 had	 no	 structure,	 with	 a	 strong	
minimum	~195	nm.	By	contrast,	its	cyclised	derivative	9	and	β-
elimination	 product	 10	 had	 64%	 and	 42%	 helicity	 in	 10	 mM	
phosphate	buffer	(Fig.	2B).	In	50%	TFE,	helicity	increased	for	9	
(79%)	 and	 10	 (84%)	 (Fig.	 S2).	 Further,	 10	 had	 less	 molar	
ellipticity	 at	 220	 nm	 and	 a	 smaller	 [θ]220/[θ]205	 ratio	 than	 9,	
consistent	with	a	more	extended	helix	in	10.	This	suggests	that	
only	a	minor	carbohydrate	change	affects	peptide	structure.	
	
Fig.	2	CD	spectra	of	the	 linear	and	cyclic	pentapeptides	 in	10	mM	phosphate	solution	
(PBS)	(pH	=	7.4)	at	25	°C.	A)	6	(black),	7	(blue);	B)	8	(brown),	9	(red),	10	(pink).	
Detailed	analyses	of	1D	and	2D	NMR	spectra	revealed	that	9	
was	 α-helical,	 whilst	 10	 had	 more	 310-helicity,	 in	 water.	 The	
amide-NH	 coupling	 constant	 (3JNH–CHα)	 for	 three	 sequential	
amino	acids	Lys	1,	Ala	2,	Ala	3	 in	both	9	and	10	was	<	6.0	Hz,	
indicating	 helical	 structures.	 The	 corresponding	 values	 in	 9	
were	 slightly	 smaller	 than	10,	 suggesting	 an	α-helix	 in	9	 and	
310-helix	in	10.	Further,	the	temperature	coefficients	(Δδ/T)	for	
Ala	4,	Ser	5	amide	protons	and	one	C-terminal	NH	in	9	were	<	
–4.0	 ppb/K,	 indicating	 three	 potential	 intra-molecular	
hydrogen	 bonds	 characteristic	 of	 an	  α-helix.	 However,	 in	10	
only	Ala	4	and	one	C-terminal	NH2	proton	showed	Δδ/T	<	–4.0	
ppb/K,	with	slightly	higher	values	for	Ala	3	(4.9	ppb/K)	and	Ser	
5	 (4.6	 ppb/K).	 These	 results	 suggested	 four	 intra-molecular	
hydrogen	bonds,	but	the	later	two	were	weaker	as	expected	of	
a	 310-helix.	 Moreover,	 all	 five	 α-protons	 of	 9	 shifted	 upfield	
more	 than	 0.1	 ppm	 compared	 with	 random	 coil	 values,	
consistent	with	a	stable	α-helical	structure,	whereas	only	four	
α-protons	 shifted	upfield	 for	10	with	 the	exception	of	Hα	 for	
Ser	5	 (Fig.	3).	 These	data	 support	 the	CD	 spectral	 results	and	
indicate	 more	 α-helix	 in	 9	 than	 in	 10.	 Although	 we	 did	 not	
observe	the	dαN	(i,	i	+	4)	ROE	cross-peaks	in	9	or	10,	dαβ	(i,	i	+	3)	
ROE	cross-peak	in	9	supports	α-helicity,	whilst	stronger	dαN	(i,	i	
+	1)	ROE	and	more	dαN	(i,	i	+	2)	cross-peaks	in	10	are	consistent	
with	a	more	elongated	310-helix.	
	
Fig.	3	NMR	summary	for	the	two	cyclic	pentapeptides	9	(A)	and	10	(B)	in	90%	H2O	:	10%	
D2O.	 	For	temperature	coefficients	(∆δ/T),	solid	circle	means	<	4	ppb/K,	hollow	circles	
4.0–5.0	ppb/K.	Bar	thickness	indicates	the	intensity	of	ROE	cross-peaks.	
2D	ROESY	experiments	confirmed	the	connectivity	between	
sugar	 protons	 and	 peptide	 components	 (Fig.	 4).	 The	 ROE	
crosspeak	between	Lys	side	chain	εNH	and	H5	of	carbohydrate	
in	9	was	not	present	in	10,	as	H5	was	eliminated	by	conjugated	
double	 bond	 formation.	 Very	 weak	 ROEs	 were	 observed	
between	sugar	protons	H3	or	H4	to	the	β-protons	of	Ala2	and	
Ala3	 (H3	 and	 H4	 overlap).	 More	 ROEs	 in	 10	 were	 observed	
between	carbohydrate	protons	 to	peptide	backbone	and	side	
chains,	 illustrating	 the	 carbohydrate	 ring	 is	 closer	 to	 the	
peptide	backbone	relative	to	9.	The	notable	ROE	between	the	
side	 chain	 NH	 of	 lysine	 to	 H1	 of	 sugar	 and	 one	 of	 the	β	
protons	 of	 Ser	 5	 in	 10	 revealed	 the	 side	 chain	 of	 Lys	 1	
displaying	 some	 parallel	 characteristic	 to	 the	 axis	 of	 peptide	
compared	to	9.	All	of	these	data	suggested	a	more	elongated	
helical	structure,	such	as	a	310–helix,	for	10.	
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Fig.	 4	 Connectivity	 between	 carbohydrate	 and	 peptide	 regions	 in	 cyclised	
pentapeptides	 9	 (A)	 and	 10	 (B),	 with	 double	 headed	 arrows	 showing	 ROEs	 from	 1H	
NMR	 spectra	measured	 in	 90%	H2O	 :	 10%	 D2O.	 Relative	 intensity	 of	 cross-peaks	 are	
colour	coded:	red,	strong;	pink,	medium;	blue,	weak;	and	orange,	very	weak.	
A	Ramachandran	plot	of	phi	and	psi	angles	for	the	average	
20	lowest	structures	of	9	and	10	showed	that	four	out	of	five	
residues	 of	 9	 located	 in	 the	  typical	 α-helix	 allowed	 region,	
whilst	three	of	five	were	in	the	helical	region	for	10	(Fig.	5).	
	
Fig.	5		Ramachandran	plots	of	(ϕ,	ψ)	angles	derived	from	the	average	of	the	20	lowest	
energy	NMR-derived	 solution	 structures	 calculated	 for	 compound	9	 (A)	 and	10	 (B)	 in	
water.	 The	 dihedral	 angles	 for	 Ser	 5	 in	 9	 and	 for	 Ala	 3	 and	 Ala	 4	 in	 10	 are	 located	
outside	of	α-helix	allowed	region	(dashed	boxes).	
Finally,	 three-dimensional	 solution	 structures	 were	
calculated	 for	9	 and	10	 in	water.	 Compound	9	 had	 a	 smaller	
average	 pairwise	 backbone	 root-mean-square	 deviation	
(RMSD	0.389	Å)	than	10	 (RMSD	0.540	Å)	 from	an	 idealised	α-
helix	 in	 water.	 Conversely,	 the	 structure	 for	 10	 showed	 a	
smaller	 RMSD	 deviation	 from	 an	 idealised	 310-helix	 (0.307	 Å)	
than	 did	 9	 (0.852	 Å)	 (Fig	 6).	 Furthermore,	 the	 Cα	 to	 Cα	
distance	 between	 residues	 i	 and	 i	 +	 4	 in	 9	 was	 6.0	 Å,	 in	
agreement	with	an	idealised	α-helix,	whilst	the	corresponding	
distance	in	10	was	7.2	Å	which	agrees	with	a	310-helix.		
To	further	study	the	 influence	of	 linker	 length	on	structure	
of	the	peptide	backbone,	lysine	was	replaced	by	ornithine	with	
the	 shorter	 linker	 to	 give	 the	 two	 corresponding	 cyclised	
peptides	Ac-(cyclo-1,5)-[S*AAAO]-NH2	 (11)	 and	Ac-(cyclo-1,5)-
[OAAAS*]-NH2	(12).	By	CD	spectra,	the	helicity	of	11	increased	
from	34%	to	47%	in	10	mM	phosphate	buffer	pH	7.4	at	room	
temperature	 compared	 to	 the	 cyclised	 homologue	 7	
containing	 lysine.	 However,	 the	 reversed	 sequence	 (12)	 had	
significantly	reduced	helicity	(22%)	relative	to	11	(Fig.	S3).		
	
Fig.	6		Twenty	lowest	energy	NMR	structures	(green)	for	9	(left,	RMSD	0.351	Å)	and	10	
(right,	RMSD	0.176	Å)	in	90%	H2O	:	10%	D2O	onto	an	idealized	α-helix	(orange)	or	310-
helix	(yellow).	The	structure	of	9	is	more	compressed	while	10	is	more	elongated.	
With	 the	 optimal	 linker	 established,	 we	 compared	 the	α-
helicity	when	different	amino	acids	were	incorporated	into	the	
middle	of	the	peptide,	such	as	charged	(Arg	13,	Asp	17),	polar	
uncharged	 (Gln	 15),	 hydrophobic	 (Leu	 14,	 Phe	 16)	 and	 helix	
breaking	 (Gly	 18)	 residues	 (Fig.	 7).	 CD	 spectra	 showed	 that,	
relative	 to	 alanine	 (9),	 α-helicity	 was	 maintained	 for	 amino	
acids	arginine	(13),	leucine	(14),	glutamine	(15),	aspartate	(17).	
These	 amino	 acids	 also	 favour	 helicity	 in	 protein	 α-helices.17	
Phenylalanine	 (16)	 conferred	much	 less	helicity,	while	glycine	
(18)	 showed	 negligible	 helicity,	 both	 results	 being	 consistent	
with	their	lower	helical	propensities	in	proteins.17	Surprisingly,	
arginine	(13)	showed	a	little	less	helicity	than	9,	14,	15	and	17,	
perhaps	 due	 to	 hydrogen	 bonding	with	 GlcA	 competing	with	
the	peptide	backbone.	Peptides	9,	13-15	and	17	showed	helix-
characterising	 ellipticity	 double	 minima	 in	 CD	 spectra,	 with	
small	intensity	variations	due	to	different	local	environments.		
	
Fig.	7	 	(A)	CD	spectra	of	9	 (black),	13	 (green),	14	 (blue),	15	 (brown),	16	 (magenta),	17	
(cyan),	18	(orange)	in	10	mM	phosphate	(pH=	7.4).	(B)	%	helicity	of	different	peptides.	
In	 summary,	 glucuronic	 acid	 is	 used	 here	 as	 a	 linker	 to	
bridge	 the	 side	 chains	 of	 two	 native	 amino	 acids,	 and	 we	
demonstrate	 that	 this	 constraint	 can	 fold	 the	 pentapeptide	
backbone	 into	α-helix	 or	 310-helix	 structures.	 CD	 and	 2D	
1H-
NMR	 spectra	 support	 induction	 of	 these	 structures,	 which	
were	 absent	 in	 uncyclised	 linear	 peptides.	 This	 is	 the	 first	
demonstration	 that	a	 simple	 carbohydrate	 can	act	as	a	 linker	
for	stabilising	peptides	in	helical	structures.	This	novel	stapling	
strategy	 expands	 the	 portfolio	 of	 techniques	 available	 for	
fixing	 helical	 structures	 in	 short	 peptides.	 Glycosylated	
peptides	 have	 potential	 for	 improving	 the	 properties	 of	
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peptides,	 such	 as	 solubility,	 permeability,	 and	 resistance	 to	
protease	cleavage,	which	will	be	investigated	in	future.		
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